Literature DB >> 2561134

Potentiated endothelin-1-induced phosphoinositide hydrolysis in atria and mesenteric artery of DOCA-salt hypertensive rats.

J de Champlain1, H Eid, D Papin.   

Abstract

The effect of endothelin-1 on the phosphoinositide pathway was studied in slices of atria and mesenteric artery from normotensive and hypertensive (DOCA-salt) rats. Endothelin-1 induced a dose-dependent increase in inositol monophosphate production in both groups, but the reactivity of the phosphoinositide pathway was enhanced in DOCA-salt hypertensive rats. Endothelin-1 was more potent than noradrenaline and activation by these two agonists combined was additive. The phosphoinositide activation induced by endothelin-1 was independent of extracellular calcium, and was not prevented by nifedipine treatment or by removing calcium from the incubation medium. Endothelin-1 is a potent direct activator of the phosphoinositide pathway in cardiovascular tissues, and this effect is potentiated in DOCA-salt hypertension.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2561134     DOI: 10.1097/00004872-198900076-00064

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  4 in total

1.  Endothelin-1-induced contraction in isolated aortae from normotensive and DOCA-salt hypertensive rats: effect of magnesium.

Authors:  P Laurant; A Berthelot
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

Review 2.  DOCA-Salt Hypertension: an Update.

Authors:  Tyler Basting; Eric Lazartigues
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

3.  The effect of ischaemia-reperfusion on [3H]inositol phosphates and ins(1,4,5)P3 levels in cardiac atria and ventricles--a comparative study.

Authors:  R Mouton; S Genade; B Huisamen; M Malan; A Lochner
Journal:  Mol Cell Biochem       Date:  1992-10-07       Impact factor: 3.396

Review 4.  Left Atrial Myocardium in Arterial Hypertension.

Authors:  Jens Kockskämper; Florentina Pluteanu
Journal:  Cells       Date:  2022-10-08       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.